Videos

Heather Wakelee, MD, discusses maintenance therapy for patients with lung cancer.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.

S. Gail Eckhardt, MD, discusses the role of angiogenesis inhibitors for the treatment of metastatic colorectal cancer (mCRC), following the approval of aflibercept.

Jonathan D. Herman, MD, obstetrician and gynecologist at Hofstra North Shore - LIJ Medical School, discusses the findings from a survey looking at breast cancer risk perception.

Sandra Swain, MD, discusses pregnancy-related breast cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Julie R. Brahmer, MD, discusses tumor vaccines for patients with lung cancer.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an update on targeted therapies for the treatment of patients with ovarian cancer.

Harvey I. Pass, MD, discusses blood-based markers in lung cancer.

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Jennifer Woyach, MD, discusses the benefit of a combination therapy with ibrutinib for patients with chronic lymphocytic leukemia (CLL).

Carol Bush, BS, RN, discusses the role of oncology nurse navigators in healthcare reform.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, discusses the background of the prophage G-200 vaccine for recurrent glioblastoma multiforme.

Andre Goy, MD, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL)

Silvia Novello, MD, PhD, discusses some of the grey areas in lung cancer care.

Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, gives an overview of on-target and off-target side effects from anticancer targeted agents.

Craig L. Tendler, MD, discusses the mechanism of action of ibrutinib in various tumor types.

Cameron J. Turtle, MD, PhD, discuses the relationship between CD4 and CD8 T cells in patients with B-cell malignancies.

Torsten O. Nielsen discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Daniel H. Fowler, MD, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.

Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses a trial comparing two doses of ipilimumab for patients with metastatic melanoma.

Bonnie Addario, a lung cancer survivor, discusses toxicities involved during lung cancer treatment.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses the utility for vinegar as a screening tool in the U.S.

Richard Finn, MD, from UCLA's Jonsson Comprehensive Cancer Center, discusses the difficulties of treating liver cancer.

Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses patient response to immunotherapy.

Ben Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.

Howard L. Kaufman, MD, says that the oncology community is in its infancy in terms of selecting and sequencing immunotherapies for patients with melanoma.

Corey J. Langer, MD, from the Abramson Cancer Center, discusses recent advancements in treating an ALK mutation in patients with non-small cell lung cancer.

Andrew D. Seidman, MD, from Memorial Sloan-Kettering Cancer Center, discusses breast cancer treatment with surgery and radiotherapy.

Giorgio V. Scagliotti, MD, PhD, from the University of Turin, San Luigi Hospital, Orbassano, Italy, discusses afatinib in patients with EGFR-mutated tumors.